New Methods for Evaluating Preventive Migraine Treatment
Key facts
- Where
- Aarhus C and Aarhus N, DenmarkSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07071506, who can take part
Where in Denmark
- Department of Psychology and Behavioral sciences, Aarhus BSS, Aarhus UniversityAarhus C, DenmarkTaking people
- Department of Neurology, Aarhus University HospitalAarhus N, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT07071506
- Record updated
- 19 May 2026
- Original description
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.Read full original descriptionShow less
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.
Inclusion: Adults (18-65 years); ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria; Known chronic migraine (headache occurring ≥ 15 days per month for > 3 months, which on at least 8 days per month has the features of migraine headache) diagnosed before age 65; Eligibility for preventive migraine treatment; Ability to speak and read Danish.
Exclusion: Use of onabotulinumtoxinA as preventive migraine treatment during the 4 months before inclusion; Use of opioid or barbiturate medications in the last four weeks before inclusion; Secondary headache disorders including medication overuse headache; Severe psychiatric, vascular disease, or known liver disease; Use of other preventive migraine treatment except CGRP antagonists (However, participants are allowed to be on two stable preventive medication (antidepressant, calcium channel blockers, beta blockers or antiepileptic)- 2 months prior to inclusion until end of study), devices for migraine prevention such as transcranial magnetic stimulation and use of nerve blocks 3 months prior to inclusion; Alcohol abuse or substance abuse; Current or planned pregnancy and lactation.